Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sequential and Personalized Pharmacokinetic-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allogeneic Haematopoietic Stem Cell Transplantation in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning

NCT04451200 is registered in ClinicalTrials.gov with Institut Paoli-Calmettes as lead sponsor.

NCT NCT04451200
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04451200 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sequential and Personalized Pharmacokinetic-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allogeneic Haematopoietic Stem Cell Transplantation in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning
Lead sponsor
Institut Paoli-Calmettes
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 30, 2020
Completion date
December 31, 2028
Enrollment
82 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia, mielodysplasic syndrome, myeloproliferative neoplasm